000036771 001__ 36771
000036771 005__ 20240109134254.0
000036771 0247_ $$2doi$$a10.1186/s12872-015-0137-7
000036771 0248_ $$2sideral$$a93162
000036771 037__ $$aART-2015-93162
000036771 041__ $$aeng
000036771 100__ $$aFernández, S.
000036771 245__ $$aAntithrombotic treatment in elderly patients with atrial fibrillation: A practical approach
000036771 260__ $$c2015
000036771 5060_ $$aAccess copy available to the general public$$fUnrestricted
000036771 5203_ $$aBackground: Atrial fibrillation (AF) in the elderly is a complex condition. It has a direct impact on the underuse of antithrombotic therapy reported in this population. Discussion: All patients aged =75years with AF have an individual yearly risk of stroke >4%. However, the risk of hemorrhage is also increased. Moreover, in this population it is common the presence of other comorbidities, cognitive disorders, risk of falls and polymedication. This may lead to an underuse of anticoagulant therapy. Direct oral anticoagulants (DOACs) are at least as effective as conventional therapy, but with lesser risk of intracranial hemorrhage. The simplification of treatment with these drugs may be an advantage in patients with cognitive impairment. The great majority of elderly patients with AF should receive anticoagulant therapy, unless an unequivocal contraindication. DOACs may be the drugs of choice in many elderly patients with AF. Summary: In this manuscript, the available evidence about the management of anticoagulation in elderly patients with AF is reviewed. In addition, specific practical recommendations about different controversial issues (i.e. patients with anemia, thrombocytopenia, risk of gastrointestinal bleeding, renal dysfunction, cognitive impairment, risk of falls, polymedication, frailty, etc.) are provided.
000036771 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000036771 590__ $$a1.916$$b2015
000036771 591__ $$aCARDIAC & CARDIOVASCULAR SYSTEMS$$b72 / 124 = 0.581$$c2015$$dQ3$$eT2
000036771 592__ $$a1.035$$b2015
000036771 593__ $$aCardiology and Cardiovascular Medicine$$c2015$$dQ1
000036771 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000036771 700__ $$aFormiga, F.
000036771 700__ $$aCamafort, M.
000036771 700__ $$aRodrigo, J.C.
000036771 700__ $$0(orcid)0000-0002-3132-2171$$aDíez-Manglano, J.$$uUniversidad de Zaragoza
000036771 700__ $$aReino, P.
000036771 700__ $$aTiberio, G.
000036771 700__ $$aMostaza, J.M.
000036771 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000036771 773__ $$g15, 143 (2015), [10 pp.]$$pBMC cardiovasc. disord.$$tBMC CARDIOVASCULAR DISORDERS$$x1471-2261
000036771 8564_ $$s470331$$uhttps://zaguan.unizar.es/record/36771/files/texto_completo.pdf$$yVersión publicada
000036771 8564_ $$s97292$$uhttps://zaguan.unizar.es/record/36771/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000036771 909CO $$ooai:zaguan.unizar.es:36771$$particulos$$pdriver
000036771 951__ $$a2024-01-09-13:32:14
000036771 980__ $$aARTICLE